Microba Life Sciences completed the stage 1 activity screening for its autoimmune disease program in collaboration with Ginkgo Bioworks.

Of 1821 strains analyzed through Microba's data-driven drug discovery platform, 62% exhibited significant immunomodulatory activity, with an additional 18% impacting the inflammasome.

Thirty-six strains have advanced to Stage 2 functional screening, scheduled for completion in the fourth quarter of FY24, to facilitate lead candidate selection.

The autoimmune disease program is a substantial investment for Microba, valued at US$7 million ($10.6 million), and the positive results reinforce the significance of the company's data-driven therapeutic platform, potentially impacting its valuation in the therapeutic market estimated to reach US$288 billion ($434.85 billion) by 2028.